Rawan Alfroukh is a health economist and clinical pharmacist with extensive experience in pharmacoeconomics, health technology assessment, and outcomes research. She holds an MSc in Health Economics and Pharmacoeconomics from Pompeu Fabra University, where her dissertation focused on the cost-effectiveness of CAR T-cell therapy. She currently works as a Health Economics & Outcomes Research Modeling Consultant, with hands-on experience in cost-effectiveness, cost-utility, and budget impact analyses across multiple therapeutic areas. She has contributed to peer-reviewed economic evaluation publications and presented research at international and regional conferences. In 2026, she received second place for an oral presentation on the cost-effectiveness of brentuximab vedotin in advanced Hodgkin lymphoma from a Saudi payer perspective.